Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MicroRNA 4293 (miR-4293) is a small, non-coding RNA molecule that regulates gene expression by binding to the 3′ untranslated regions (UTRs) of target mRNAs, leading to their degradation or inhibition of translation. miR-4293 has been shown to be significantly upregulated in non-small cell lung carcinoma tissue and cell lines, promoting tumor cell proliferation, migration, and metastasis while suppressing apoptosis. Mechanistically, miR-4293 targets and downregulates the mRNA-decapping enzyme DCP2, which in turn affects the stability of long non-coding RNA WFDC21P. This leads to the increased expression of WFDC21P and activation of the STAT3 signaling pathway. The oncogenic activity of miR-4293 in lung cancer is mediated through this axis. miR-4293 is considered a potential diagnostic and therapeutic target for certain cancers, but there are currently no approved drugs that directly interact with it.
Antisense oligonucleotides against miR-4293 can inhibit its function in cell models
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MicroRNA 4293 (miR-4293).